Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on Elranatamab for Patients with Multiple Myeloma Continuing from Previous Clinical Trials

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Multiple Myeloma, a type of cancer that affects plasma cells in the bone marrow. The treatment being used in this study is called Elranatamab, which is a solution for injection developed by Pfizer Inc. The purpose of the study is to monitor the safety of Elranatamab in participants who have previously been part of other Pfizer-sponsored studies involving this medication.

Participants in this study will continue to receive Elranatamab if they have completed a previous study and are still benefiting from the treatment. The study is designed to be open-label, meaning that both the participants and the researchers know what treatment is being administered. The study will not involve a placebo, and all participants will receive the active treatment.

Throughout the study, researchers will closely monitor participants for any side effects, including both non-serious and serious adverse events. The study aims to ensure that Elranatamab remains safe for use in treating Multiple Myeloma over an extended period. Participants will receive the treatment through subcutaneous injections, which means the medication is injected under the skin. The study is expected to continue until 2027, providing ongoing access to the treatment for those who are benefiting from it.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants must have completed a qualifying parent study and were still receiving elranatamab when the parent study ended. Participants should be experiencing clinical benefits from elranatamab as determined by the investigator.

    Participants must agree to follow the contraceptive and barrier guidance provided by the study.

  2. Step 2

    Medication administration

    Elranatamab is administered as a solution for injection. The route of administration is subcutaneous, meaning the injection is given under the skin.

    The specific dosage, frequency, and duration of administration will be determined by the study protocol and the investigator overseeing the participant's care.

  3. Step 3

    Monitoring and safety

    The main objective of the study is to monitor the safety of elranatamab. This includes observing for any nonserious adverse events that may lead to the permanent discontinuation of the medication.

    All serious adverse events (SAEs) will be recorded and assessed throughout the study duration.

  4. Step 4

    Study duration

    The estimated end date for the study is March 1, 2027. Participants will continue to receive elranatamab and be monitored until this date or until the study is otherwise concluded.

Who can join the trial?

6 criteria

  • Participants must agree to follow the Contraceptive and Barrier Guidance. This means they need to use methods to prevent pregnancy during the study.
  • Participants must have completed a qualifying Parent Study. This means they were part of an earlier related study.
  • Participants must have been receiving elranatamab when the Parent Study ended. Elranatamab is a medication used in the study.
  • Participants must be getting a clinical benefit from elranatamab, as determined by the investigator. This means the medication should be helping them, according to the study doctor.
  • Both male and female participants are eligible to join the study.
  • The study includes people from vulnerable populations. This means it may include groups who need special protection or care.

Who cannot join the trial?

4 criteria

  • Patients who have a different condition than multiple myeloma cannot participate. Multiple myeloma is a type of cancer that affects certain cells in the bone marrow.
  • Patients who are not within the specified age range cannot participate. The age range is typically defined by the study.
  • Patients who are not part of the specified clinical trial group cannot participate. Clinical trial groups are categories used to organize participants based on certain characteristics.
  • Patients who are considered part of a vulnerable population cannot participate. A vulnerable population includes individuals who may have a higher risk of harm or exploitation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Elranatamab is a medication being studied for its effects on multiple myeloma, a type of blood cancer. In this clinical trial, the main goal is to monitor the safety of this medication in participants who have already been part of previous studies sponsored by Pfizer. Elranatamab is designed to help the immune system target and fight cancer cells more effectively.

What is already known about the treatment

Elranatamab – Elranatamab is administered as an injection, typically given under the skin. It is currently being studied in clinical trials, particularly for its safety in treating multiple myeloma, a type of blood cancer. The medication works by targeting specific proteins on cancer cells, helping the immune system to recognize and destroy these cells. It is classified as a monoclonal antibody, which is a type of targeted cancer therapy.

Investigated diseases

Multiple Myeloma – Multiple myeloma is a type of cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, cancerous plasma cells multiply and accumulate in the bone marrow, leading to bone damage and affecting the production of normal blood cells. As the disease progresses, it can cause bone pain, fractures, and anemia due to the reduced production of healthy blood cells. Patients may also experience high levels of calcium in the blood, kidney problems, and increased susceptibility to infections. The disease often progresses slowly, but it can become more aggressive over time.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-505200-33-00Protocol codeC1071015Estimated enrolment80 patientsSponsorPfizer Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.